Skip to main content

Advertisement

SpringerLink
Log in

Sepsis und Mortalität nach schwerwiegenden Infektionen

Wie epidemiologische Daten tierexperimentelle Ergebnisse bestätigen

Sepsis and mortality after severe infections

How epidemiological data confirm results of animal experiments

  • Forschung aktuell
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869–871

    Article  CAS  PubMed  Google Scholar 

  2. Galloway J, Hyrich L, Mercer L et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50:124–131. https://doi.org/10.1093/rheumatology/keq242

    Article  CAS  PubMed  Google Scholar 

  3. George MD, Baker JF, Hsu JY, Wu Q, Xie F, Chen L, Yun H, Curtis J (2016) Preoperative Timing of Infliximab and Risk of Post-Operative Infection in a Medicare Cohort [abstract]. Arthritis Rheumatol 68(suppl 10). http://acrabstracts.org/abstract/preoperative-timing-of-infliximab-and-risk-of-post-operative-infection-in-a-medicare-cohort/. Accessed August 25, 2017

  4. Qiu P, Cui X, Sun J et al (2013) Anti-tumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. Crit Care Med. https://doi.org/10.1097/CCM.0b013e3182982add

    PubMed  PubMed Central  Google Scholar 

  5. Richter A, Listing J, Schneider M (2016) The impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Ann Rheum Dis 75(9):1667–1673. https://doi.org/10.1136/annrheumdis-2015-207838

    Article  CAS  PubMed  Google Scholar 

  6. Strangfeld A, Eveslage M, Schneider M et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914–1920

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Touloumis A, Agresti A, Kateri M (2013) GEE for Multinomial responses using a local odds ratios parameterization. Biometrie 69:633–640

    Article  Google Scholar 

  8. Tracey KJ, Fong Y, Hesse DG et al (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662–664

    Article  CAS  PubMed  Google Scholar 

  9. Waage A, Halstensen A, Espevik T (1987) Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 329:355–357

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Deutsches Rheuma-Forschungszentrum Berlin, Programmbereich Epidemiologie, ein Leibniz Institut, Charitéplatz 1, 10117, Berlin, Deutschland

    A. Strangfeld

Authors
  1. A. Strangfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Strangfeld.

Ethics declarations

Interessenkonflikt

A. Strangfeld erhielt Honorare für Referententätigkeiten von den Firmen AbbVie, BMS, Lilly, MSD, Pfizer, Roche und UCB. Das deutsche Biologika-Register RABBIT wird gemeinsam durch AbbVie, BMS, Celltrion, Hospira, MSD, Pfizer, Roche, Samsung und UCB unterstützt. Die Studienleitung besitzt volle akademische Freiheit in der Durchführung, Analyse und Publikation der Ergebnisse.

Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren. Die RABBIT-Studie erhielt 2001 die Zustimmung der Ethikkommission der Charité-Universitätsmedizin Berlin.

Additional information

Redaktion

A. Radbruch, Berlin

R.E. Schmidt, Hannover

U. Wagner, Leipzig

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Strangfeld, A. Sepsis und Mortalität nach schwerwiegenden Infektionen. Z Rheumatol 76, 776–779 (2017). https://doi.org/10.1007/s00393-017-0374-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-017-0374-5

Search

Navigation